SMAD4 Protein Expression and Survival Outcomes in Resected PDAC

Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited prognostic biomarkers after curative-intent resection. We aim to determine if loss of SMAD4 protein expression has prognostic significance in operated PDAC patients. Methods: SMAD4 protein expression was evaluated by immunohistochemistry (IHC) in resected PDAC tu-mours from patients treated at two centers. The prognostic significance of SMAD4 expression status and clinical outcomes, namely overall survival (OS) and recurrence-free survival (RFS), was assessed using survival analysis with Kaplan–Meier estimation and Cox proportional hazards regression models. Results: A total of 87 patients with resected PDAC were included in the final analysis, with a median follow-up of 75.9 months. In univariable analysis, SMAD4 expression status was not associated with OS (intact vs. lost: HR = 0.87, p = 0.56) or RFS (HR = 0.84, p = 0.51). In multivariable analysis, SMAD4 expression was not an independent prognostic factor for OS (HR = 0.94, p = 0.81) or RFS (HR = 0.82, p = 0.49). Established clinicopathological variables, including histological grade, nodal status, postoperative CA19-9 levels, and adju-vant treatment, were independently associated with both survival outcomes, while resection status was inde-pendently associated with OS. Conclusions: In this bicentric cohort, loss of SMAD4 expression assessed by IHC was not an independent prognostic marker for OS or RFS of resected PDAC. Despite the potential SMAD4 relevance within specific biological or clinical subgroups, further studies are warranted to clarify the role of SMAD4 in PDAC risk strati-fication and support the development of integrated molecular and clinicopathological prognostic models.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-18
DOI
https://doi.org/10.20944/preprints202611.1900.v1
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

SMAD4 Protein Expression and Survival Outcomes in Resected PDAC

Ivo Sousa-Ferreira, Luís Mascarenhas‐Lemos, Rui Maio, José Passos Coelho et al.
Preprints.org
Pancreatic and Hepatic Oncology Research
preprint

SMAD4 Protein Expression and Survival Outcomes in Resected PDAC

Ivo Sousa-Ferreira, Luís Mascarenhas‐Lemos, Rui Maio, José Passos Coelho, João Paulo Martins, Joana Cardoso, Tânia Rodrigues, Mariana Câmara, Ana Faria
preprint en

Abstract

Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited prognostic biomarkers after curative-intent resection. We aim to determine if loss of SMAD4 protein expression has prognostic significance in operated PDAC patients. Methods: SMAD4 protein expression was evaluated by immunohistochemistry (IHC) in resected PDAC tu-mours from patients treated at two centers. The prognostic significance of SMAD4 expression status and clinical outcomes, namely overall survival (OS) and recurrence-free survival (RFS), was assessed using survival analysis with Kaplan–Meier estimation and Cox proportional hazards regression models. Results: A total of 87 patients with resected PDAC were included in the final analysis, with a median follow-up of 75.9 months. In univariable analysis, SMAD4 expression status was not associated with OS (intact vs. lost: HR = 0.87, p = 0.56) or RFS (HR = 0.84, p = 0.51). In multivariable analysis, SMAD4 expression was not an independent prognostic factor for OS (HR = 0.94, p = 0.81) or RFS (HR = 0.82, p = 0.49). Established clinicopathological variables, including histological grade, nodal status, postoperative CA19-9 levels, and adju-vant treatment, were independently associated with both survival outcomes, while resection status was inde-pendently associated with OS. Conclusions: In this bicentric cohort, loss of SMAD4 expression assessed by IHC was not an independent prognostic marker for OS or RFS of resected PDAC. Despite the potential SMAD4 relevance within specific biological or clinical subgroups, further studies are warranted to clarify the role of SMAD4 in PDAC risk strati-fication and support the development of integrated molecular and clinicopathological prognostic models.

Preprints.org
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon